The Spallation Neutron Source — already the world’s most powerful accelerator-based neutron source — will be on a planned hiatus through June 2024 as crews work to upgrade the facility. Much of the work — part of the facility’s Proton Power Upgrade project — will involve building a connector between the accelerator and the planned Second Target Station.
ORNL hosted its annual Smoky Mountains Computational Sciences and Engineering Conference in person for the first time since the COVID-19 pandemic.
The Oak Ridge Leadership Computing Facility, a Department of Energy Office of Science user facility at ORNL, is pleased to announce a new allocation program for computing time on the IBM AC922 Summit supercomputer.
Carl Dukes’ career as an adept communicator got off to a slow start: He was about 5 years old when he spoke for the first time. “I’ve been making up for lost time ever since,” joked Dukes, a technical professional at the Department of Energy’s Oak Ridge National Laboratory.
The Department of Energy’s Office of Science has selected three ORNL research teams to receive funding through DOE’s new Biopreparedness Research Virtual Environment initiative.
Neutron experiments can take days to complete, requiring researchers to work long shifts to monitor progress and make necessary adjustments. But thanks to advances in artificial intelligence and machine learning, experiments can now be done remotely and in half the time.
A new nanoscience study led by a researcher at ORNL takes a big-picture look at how scientists study materials at the smallest scales.
A licensing agreement between the Department of Energy’s Oak Ridge National Laboratory and research partner ZEISS will enable industrial X-ray computed tomography, or CT, to perform rapid evaluations of 3D-printed components using ORNL’s machine
A group at the Department of Energy's Oak Ridge National Laboratory made a difference for local youth through hands-on projects that connected neutron science and engineering intuitively.
After a highly lauded research campaign that successfully redesigned a hepatitis C drug into one of the leading drug treatments for COVID-19, scientists at ORNL are now turning their drug design approach toward cancer.